Dilated cardiomyopathy medical therapy
|
Dilated cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dilated cardiomyopathy medical therapy On the Web |
|
American Roentgen Ray Society Images of Dilated cardiomyopathy medical therapy |
|
Risk calculators and risk factors for Dilated cardiomyopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-in-Chief: Abdelrahman Ibrahim Abushouk, MD[2]; Sachin Shah, M.D.
Medical therapy
Medical therapy for dilated cardiomyopathy (DCM) is centered on guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), treatment of reversible etiologies when identified, and prevention of disease-related complications. Contemporary therapy is based on four foundational drug classes:
- Angiotensin receptor-neprilysin inhibitor (ARNI) or angiotensin-converting enzyme inhibitor (ACE inhibitor) / angiotensin receptor blocker (ARB)
- Evidence-based beta blocker
- Mineralocorticoid receptor antagonist (MRA)
- Sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor)
Rapid initiation of all four therapies is recommended whenever feasible. The goal is to achieve target or maximally tolerated doses of all four drug classes within 3 months of diagnosis.[1] [2]
Renin-angiotensin system inhibition
Sacubitril/valsartan is the preferred renin-angiotensin system inhibitor in patients with symptomatic HFrEF.
| Therapy | Starting dose | Target dose |
|---|---|---|
| Sacubitril/valsartan | 24/26 mg or 49/51 mg twice daily | 97/103 mg twice daily |
| Enalapril | 2.5–5 mg twice daily | 10–20 mg twice daily |
| Losartan | 25–50 mg daily | 150 mg daily |
Important considerations:
- A 36-hour washout period is required when switching from an ACE inhibitor to sacubitril/valsartan.
- No washout period is required when switching from an ARB.
- Blood pressure, renal function, and serum potassium should be monitored during titration.
Evidence-based beta blockers
Only three beta blockers have demonstrated mortality benefit in HFrEF:
| Drug | Starting dose | Target dose |
|---|---|---|
| Carvedilol | 3.125 mg twice daily | 25–50 mg twice daily |
| Metoprolol succinate | 12.5–25 mg daily | 200 mg daily |
| Bisoprolol | 1.25 mg daily | 10 mg daily |
Benefits include:
- Improved left ventricular ejection fraction
- Reduced heart failure hospitalization
- Reduced all-cause mortality
- Reverse ventricular remodeling
Beta blockers should preferably be initiated in euvolemic patients.
Mineralocorticoid receptor antagonists
MRAs are recommended in symptomatic HFrEF unless contraindicated.
| Drug | Starting dose | Target dose |
|---|---|---|
| Spironolactone | 12.5–25 mg daily | 25–50 mg daily |
| Eplerenone | 25 mg daily | 50 mg daily |
Monitoring:
- Serum potassium
- Serum creatinine
- Estimated glomerular filtration rate (eGFR)
MRAs are generally recommended in patients with eGFR >30 mL/min/1.73 m² and serum potassium <5.0 mEq/L. Contraindications include significant hyperkalemia and severe renal dysfunction.
Finerenone is a nonsteroidal MRA approved for heart failure with LVEF ≥40% based on the FINEARTS-HF trial and is not currently considered a standard therapy for HFrEF.[3]
SGLT2 inhibitors
SGLT2 inhibitors are recommended regardless of diabetic status.
| Drug | Dose |
|---|---|
| Dapagliflozin | 10 mg daily |
| Empagliflozin | 10 mg daily |
| Sotagliflozin | 200–400 mg daily |
Benefits include:
- Reduced cardiovascular mortality
- Reduced heart failure hospitalization
- Early clinical benefit after initiation
Common adverse effects:
- Genital mycotic infections
- Volume depletion
- Rare euglycemic diabetic ketoacidosis
Renal considerations:
- Dapagliflozin: initiation recommended at eGFR ≥25 mL/min/1.73 m²
- Empagliflozin: no lower eGFR initiation threshold in current labeling
- Sotagliflozin: initiation recommended at eGFR ≥25 mL/min/1.73 m²
- Once initiated, SGLT2 inhibitors may generally be continued even if eGFR declines below the initiation threshold
Initiation and titration strategy
Current heart failure guidelines favor rapid initiation of all four pillars of GDMT.[2]
General principles:
- Initiate multiple drug classes early whenever feasible.
- Titrate every 1–2 weeks as tolerated.
- Monitor blood pressure, renal function, and electrolytes.
- Reassess left ventricular ejection fraction after 3–6 months of optimized therapy.
- Evaluate for device therapy if left ventricular dysfunction persists.
Additional pharmacologic therapies
Diuretics
Loop diuretics are indicated for relief of congestion and volume overload.
Common agents include:
Diuretics improve symptoms but have not been shown to reduce mortality.
Hydralazine and isosorbide dinitrate
The combination of hydralazine and isosorbide dinitrate is recommended for self-identified African American patients with NYHA class III–IV HFrEF who remain symptomatic despite optimal GDMT.
In patients of any background who cannot tolerate ARNI, ACE inhibitor, or ARB therapy because of drug intolerance, renal dysfunction, or hyperkalemia, the combination may be considered.
Typical dosing:
- Starting dose: isosorbide dinitrate 20 mg plus hydralazine 37.5 mg three times daily
- Target dose: isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily
Ivabradine
Ivabradine may be considered in patients with:
- NYHA class II–III heart failure
- Sinus rhythm
- Resting heart rate ≥70 beats/minute
- Left ventricular ejection fraction ≤35%
- Receiving GDMT including a beta blocker at maximally tolerated dose
Dosing:
- Standard starting dose: 5 mg twice daily with meals
- Use 2.5 mg twice daily in patients aged ≥75 years or with conduction abnormalities
- Target dose: 7.5 mg twice daily
Vericiguat
Vericiguat may be considered in selected high-risk patients with symptomatic chronic HFrEF, left ventricular ejection fraction ≤45%, and recent worsening heart failure despite optimized GDMT.
Dosing:
- Starting dose: 2.5 mg daily
- Target dose: 10 mg daily
Digoxin
Digoxin may be considered to reduce heart failure hospitalization in patients with symptomatic HFrEF despite GDMT. No mortality benefit has been demonstrated.
Dosing:
- 0.125–0.25 mg daily
- Lower doses should be used in elderly patients, those with renal impairment, or low lean body mass
Target serum concentration:
- 0.5–0.9 ng/mL
Concentrations ≥1.2 ng/mL are associated with increased mortality risk.
Etiology-specific medical therapy
Inflammatory and autoimmune cardiomyopathy
Selected patients with biopsy-proven virus-negative inflammatory cardiomyopathy may benefit from immunosuppressive therapy.
Potential therapies include:
- Corticosteroids
- Azathioprine
- Cyclosporine
Cardiac sarcoidosis
Corticosteroid therapy remains the cornerstone of treatment.[4]
Viral cardiomyopathy
Management is generally supportive. Specific antiviral or immunomodulatory therapies may be considered in selected cases.
Alcohol-related cardiomyopathy
Complete alcohol abstinence is recommended and may result in substantial recovery of ventricular function.[5]
Tachycardia-mediated cardiomyopathy
Treatment of the underlying arrhythmia may result in complete reverse remodeling.
Peripartum cardiomyopathy
Management includes standard heart failure therapy with pregnancy- and lactation-specific modifications.
Chagas cardiomyopathy
Antiparasitic therapy (e.g., benznidazole) may be considered during acute infection or early chronic disease. Standard GDMT should be administered when left ventricular dysfunction is present.
Nutritional cardiomyopathy
Specific deficiencies should be corrected when identified.
Examples include:
- Thiamine deficiency
- Selenium deficiency
Anticoagulation
Routine anticoagulation is not recommended in patients with DCM who remain in sinus rhythm and have no additional indication for anticoagulation.[6]
Anticoagulation is indicated for:
- Atrial fibrillation
- Documented left ventricular thrombus
- Prior thromboembolic events
For documented left ventricular thrombus in DCM, anticoagulation for at least 3–6 months is generally recommended. Longer therapy may be considered if left ventricular ejection fraction remains ≤35% or thrombus risk factors persist.
Intravenous therapies for acute decompensation
In patients with severe decompensated heart failure or cardiogenic shock, intravenous vasoactive therapy may be required.
Common agents include:
Oral milrinone has been shown to increase mortality and is contraindicated.
These therapies are generally used as a bridge to recovery, mechanical circulatory support, or heart transplantation.
References
- ↑ Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (May 2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 79 (17): e263–e421. doi:10.1016/j.jacc.2021.12.012. PMID 35379503 Check
|pmid=value (help). - ↑ 2.0 2.1 Maddox TM, Januzzi JL, Allen LA, Breathett K, Brouse S, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Walsh MN, Wasserman A, Yancy CW, Youmans QR (April 2024). "2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee". J Am Coll Cardiol. 83 (15): 1444–1488. doi:10.1016/j.jacc.2023.12.024. PMID 38466244 Check
|pmid=value (help). - ↑ Solomon SD, McMurray JJ, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CS, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GC, Llamas-Esperón G, Mareev V, Martinez FA, Melenovský V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JF, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P (October 2024). "Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction". N Engl J Med. 391 (16): 1475–1485. doi:10.1056/NEJMoa2407107. PMID 39225278 Check
|pmid=value (help). - ↑ Cheng RK, Kittleson MM, Beavers CJ, Birnie DH, Blankstein R, Bravo PE, Gilotra NA, Judson MA, Patton KK, Rose-Bovino L (May 2024). "Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association". Circulation. 149 (21): e1197–e1216. doi:10.1161/CIR.0000000000001240. PMID 38634276 Check
|pmid=value (help). - ↑ Weintraub RG, Semsarian C, Macdonald P (July 2017). "Dilated cardiomyopathy". Lancet. 390 (10092): 400–414. doi:10.1016/S0140-6736(16)31713-5. PMID 28190577.
- ↑ Levine GN, McEvoy JW, Fang JC, Ibeh C, McCarthy CP, Misra A, Shah ZI, Shenoy C, Spinler SA, Vallurupalli S, Lip GY (October 2022). "Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association". Circulation. 146 (15): e205–e223. doi:10.1161/CIR.0000000000001092. PMID 36106537 Check
|pmid=value (help).